Diarylquinolines target subunit c of mycobacterial ATP synthase
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [111]
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationMolecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., & Jacobs, W. R. (1997) · Nature Medicine · doi:10.1038/nm0597-567 · Cited by 472
Telenti, A., Honoré, N., Bernasconi, C., March, J., Ortega, A., Heym, B., Takiff, H. E., & Cole, S. T. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.719-723.1997 · Cited by 320
de Jonge, M. R., Koymans, L. H. M., Guillemont, J. E. G., Koul, A., & Andries, K. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21376 · Cited by 124
Self-citationThe F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for Growth
Tran, S. L., & Cook, G. M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.14.5023-5028.2005 · Cited by 116
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot-Pernot, C., & Jarlier, V. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-06 · Cited by 107
Wang, R., Prince, J. T., & Marcotte, E. M. (2005) · Genome Research · doi:10.1101/gr.3994105 · Cited by 86
Junge, W., & Nelson, N. (2005) · Science · doi:10.1126/science.1112617 · Cited by 60
Cited by
Items 201–300 of 571
MurF Inhibitors with Antibacterial Activity: Effect on Muropeptide Levels
Baum, E. Z., Crespo‐Carbone, S. M., Foleno, B. D., Simon, L. D., Guillemont, J., Macielag, M. J., & Bush, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00166-09 · Cited by 45
Self-citationLi, B., Ye, M., Guo, Q., Zhang, Z., Yang, S., Ma, W., Yu, F., & Chu, H. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00175-18 · Cited by 45
Berube, B. J., & Parish, T. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-17 · Cited by 47
Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger
Salina, E. G., & Makarov, V. (2022) · Microorganisms · doi:10.3390/microorganisms10122334 · Cited by 47
Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Arora, G., Misra, R., & Sajid, A. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170130111324 · Cited by 43
Moodley, R., Mashaba, C., Rakodi, G. H., Ncube, N. B., Maphoru, M. V., Balogun, M. O., Jordan, A., Warner, D. F., Khan, R. B., & Tukulula, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050576 · Cited by 43
Salina, E. G., Riabova, O., Kaprelyants, A. S., & Makarov, V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01308-13 · Cited by 45
Tuberculosis Drugs: New Candidates and How to Find More
Sala, C., & Hartkoorn, R. C. (2011) · Future Microbiology · doi:10.2217/fmb.11.46 · Cited by 48
The Anti-Tuberculosis Agents Under Development and the Challenges Ahead
Kumar, D., Negi, B., & Rawat, D. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.128 · Cited by 47
Elucidating the Mechanisms of Action of Antimicrobial Agents
HUDSON, M. A., & Lockless, S. W. (2022) · mBio · doi:10.1128/mbio.02240-21 · Cited by 42
Alcaraz, M., Sharma, B., Roquet, F., Condé, C., Cochard, T., Biet, F., Kumar, V., & Kremer, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114531 · Cited by 42
Is the GAIN Act a turning point in new antibiotic discovery?
Brown, E. D. (2013) · Canadian Journal of Microbiology · doi:10.1139/cjm-2013-0089 · Cited by 50
Multidrug and extensively drug-resistant tuberculosis
Maitre, T., Aubry, A., Jarlier, V., Robert, J., Véziris, N., Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F., et al. (2017) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2016.07.006 · Cited by 41
Anand, P., & Akhter, Y. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.05.124 · Cited by 44
F1·Fo ATP Synthase/ATPase: Contemporary View on Unidirectional Catalysis
Zharova, T. V., Grivennikova, V. G., & Borisov, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065417 · Cited by 45
Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase
Khan, S. R., Singh, S., Roy, K. K., Akhtar, M. S., Saxena, A. K., & Krishnan, M. Y. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.09.012 · Cited by 41
Moir, D. T., Opperman, T. J., Butler, M. M., & Bowlin, T. L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.004 · Cited by 40
A Cinchona Alkaloid Antibiotic That Appears To Target ATP Synthase in Streptococcus pneumoniae
Wang, X., Zeng, Y., Li, S., Larson, P. G., Liu, X., Zou, X., Wang, S., Guo, K., Ma, C., Zhang, G., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01353 · Cited by 42
Trehalose Recycling Promotes Energy-Efficient Biosynthesis of the Mycobacterial Cell Envelope
Pohane, A. A., Carr, C. R., Garhyan, J., Swarts, B. M., & Siegrist, M. S. (2021) · mBio · doi:10.1128/mbio.02801-20 · Cited by 44
Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
Wu, S.-H., Chan, H.-H., Hsiao, H.-C., & Jou, R. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.754249 · Cited by 40
Recent advances in antituberculous drug development and novel drug targets
Tomioka, H., Tatano, Y., Yasumoto, K., & Shimizu, T. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.4.455 · Cited by 46
The c-Ring of the F1FO-ATP Synthase: Facts and Perspectives
Nesci, S., Trombetti, F., Ventrella, V., & Pagliarani, A. (2015) · The Journal of Membrane Biology · doi:10.1007/s00232-015-9860-3 · Cited by 41
Berube, B. J., Russell, D., Castro, L., Choi, S., Narayanasamy, P., & Parish, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02661-18 · Cited by 43
The Lung Microbiome: A Central Mediator of Host Inflammation and Metabolism in Lung Cancer Patients?
Weinberg, F. D., Dickson, R. P., Nagrath, D., & Ramnath, N. (2020) · Cancers · doi:10.3390/cancers13010013 · Cited by 42
Sellamuthu, S., Singh, M., Kumar, A., & Singh, S. K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1327577 · Cited by 40
Ethoxyquin prevents chemotherapy‐induced neurotoxicity via Hsp90 modulation
Zhu, J., Chen, W., Mi, R., Zhou, C., Reed, N., & Höke, A. (2013) · Annals of Neurology · doi:10.1002/ana.24004 · Cited by 39
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
Diaz, J. M. A., Abulfathi, A. A., Brake, L. H. M. T., van Ingen, J., Kuipers, S., Magis-Escurra, C., Raaijmakers, J., Svensson, E. M., & Boeree, M. J. (2022) · Respiration · doi:10.1159/000528274 · Cited by 44
Esener, N., Green, M. J., Emes, R. D., Jowett, B., Davies, P. L., Bradley, A. J., & Dottorini, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-35867-6 · Cited by 36
Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis
Deshkar, A. T., & Shirure, P. A. (2022) · Cureus · doi:10.7759/cureus.28519 · Cited by 36
Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis
Makarov, V., Salina, E. G., Reynolds, R. C., Zin, P. P. K., & Ekins, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02075 · Cited by 37
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Yan, W., Zheng, Y., Dou, C. R., Zhang, G., Arnaout, T., & Cheng, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00106-y · Cited by 41
Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
Sheikh, B. A., Bhat, B. A., Mehraj, U., Mir, W. R., Hamadani, S., & Mir, M. A. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200628021702 · Cited by 37
Zhu, H., Zhou, X., Zhuang, Z., Li, L., Bi, J., & Mi, K. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1183597 · Cited by 44
Snobre, J., Villellas, M. C., Coeck, N., Mulders, W., Tzfadia, O., de Jong, B. C., Andries, K., & Rigouts, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-36955-y · Cited by 34
Self-citationNegi, A., Perveen, S., Gupta, R., Singh, P. P., & Sharma, R. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01892 · Cited by 35
Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system
Pamreddy, A., Baijnath, S., Naicker, T., Ntshangase, S., Mdanda, S., Lubanyana, H., Kruger, H. G., & Govender, T. (2018) · RSC Advances · doi:10.1039/c8ra00984h · Cited by 34
Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis
Urban, M., Šlachtová, V., & Brulíková, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113139 · Cited by 37
Towards new tuberculosis drugs
Cole, S. T., & Alzari, P. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351321 · Cited by 34
Jeffreys, L. N., Ardrey, A., Hafiz, T. A., Dyer, L.-A., Warman, A. J., Mosallam, N., Nixon, G. L., Fisher, N. E., Hong, W. D., Leung, S. C., et al. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00283 · Cited by 35
Lü, P., Villellas, C., Koul, A., Andries, K., Lill, H., & Bald, D. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.74 · Cited by 33
Self-citationGurcha, S. S., Usha, V., Cox, J. A. G., Fütterer, K., Abrahams, K. A., Bhatt, A., Alderwick, L. J., Reynolds, R. C., Loman, N. J., Nataraj, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113568 · Cited by 36
Adolph, C., McNeil, M. B., & Cook, G. M. (2022) · mBio · doi:10.1128/mbio.01672-22 · Cited by 32
“Several inhibitors of the mycobacterial respiratory chain have now 65 been identified including the only three new TB drugs to be approved in the last 50 years; 66 bedaquiline (BDQ), which inhibits the mycobacterial F1Fo ATP synthase (15-17) and 67”
BackgroundEspI regulates the ESX ‐1 secretion system in response to ATP levels in M ycobacterium tuberculosis
Zhang, M., Chen, J. M., Sala, C., Rybniker, J., Dhar, N., & Cole, S. T. (2014) · Molecular Microbiology · doi:10.1111/mmi.12718 · Cited by 37
Targeting the Histidine Pathway in Mycobacterium tuberculosis
Lunardi, J., Nunes, J., Bizarro, C. V., Basso, L. A., Santos, D. S., & Machado, P. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660203 · Cited by 32
Mechanism of Action of ME1111, a Novel Antifungal Agent for Topical Treatment of Onychomycosis
Takahata, S., Kubota, N. K., Takei‐Masuda, N., Yamada, T., Maeda, M., Alshahni, M. M., Abe, S., Tabata, Y., & Maebashi, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01790-15 · Cited by 32
Sarathy, J. P., Ragunathan, P., Cooper, C. B., Upton, A. M., Grüber, G., & Dick, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01540-19 · Cited by 32
Kamariah, N., Ragunathan, P., Shin, J. S., Saw, W. G., Wong, C. F., Dick, T., & Grüber, G. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.11.006 · Cited by 31
Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis
Jang, J., Kim, R., Woo, M., Jeong, J., Park, D. E., Kim, G., & Delorme, V. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02637-16 · Cited by 31
Islam, M. M., Alam, M. S., Liu, Z., Khatun, M. S., Yusuf, B., Hameed, H. M. A., Tian, X., Chhotaray, C., Basnet, R., Tadesse, H. A., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1304857 · Cited by 30
Guo, J., Huang, G., Wu, Q., Xie, Y., Weng, J., & Lu, G. (2019) · Organic Chemistry Frontiers · doi:10.1039/c9qo00380k · Cited by 30
Winter, H. R., Egizi, E., Murray, S. R., Erondu, N., Ginsberg, A. M., Rouse, D. J., Severynse-Stevens, D., & Pauli, E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04171-14 · Cited by 30
R207910 (TMC207) : un nouvel antibiotique pour le traitement de la tuberculose
Lounis, N., Guillemont, J., Véziris, N., Koul, A., Jarlier, V., & Andries, K. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.09.007 · Cited by 33
Self-citationReview: Managing TB in the 21st century: existing and novel drug therapies
Guy, E., & Mallampalli, A. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808099522 · Cited by 30
Pipeline of drugs for related diseases
Dooley, K. E., Nuermberger, E. L., & Diacon, A. H. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000009 · Cited by 29
Gupta, V. K., Kumar, M. M., Singh, D. K., Bisht, D., & Sharma, S. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1377346 · Cited by 30
Villamizar–Mogotocoro, A., Vargas-Méndez, L. Y., & Kouznetsov, V. V. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105374 · Cited by 29
Gao, Q., Deng, S., & Jiang, T. (2022) · Engineering Microbiology · doi:10.1016/j.engmic.2022.100047 · Cited by 30
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis
Naik, M., Ghorpade, S. R., Jena, L. K., Gorai, G., Narayan, A., Guptha, S., Sharma, S., Dinesh, N., Kaur, P., Nandishaiah, R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001933 · Cited by 31
Quinoline Derivatives as Promising Scaffolds for Antitubercular Activity: A Comprehensive Review
Owais, M., Kumar, A., Hasan, S. S., Singh, K., Azad, I., Hussain, A., Suvaiv, & Akil, M. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575281039231218112953 · Cited by 28
Insights into the Physiology and Metabolism of a Mycobacterial Cell in an Energy-Compromised State
Patil, V., & Jain, V. P. (2019) · Journal of Bacteriology · doi:10.1128/jb.00210-19 · Cited by 28
Ofori-Anyinam, B., Riley, A. J., Jobarteh, T., Gitteh, E., Sarr, B., Faal-Jawara, T. I., Rigouts, L., Senghore, M., Kehinde, A. O., Onyejepu, N., et al. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.101899 · Cited by 30
Targeting mycobacterial membranes and membrane proteins: Progress and limitations
Kumar, G., & Kapoor, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117212 · Cited by 31
Identification and synthesis of novel inhibitors of mycobacterium ATP synthase
Surase, Y. B., Samby, K., Amale, S. R., Sood, R., Purnapatre, K. P., Pareek, P. K., Das, B., Nanda, K., Kumar, S., & Verma, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.081 · Cited by 29
Gomes, N. G. M., Madureira-Carvalho, Á., da Silva, D. D., Valentão, P., & Andrade, P. B. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111756 · Cited by 29
Tong, E., Wu, Q., Chen, Y., Liu, Z., Zhang, M., Zhu, Y., Wu, K., Pan, J., 潘军航, & Jiang, J. (2023) · Antibiotics · doi:10.3390/antibiotics12091389 · Cited by 29
Silva, C. D. M., Hajihosseini, A., Myrick, J., Nole, J., Louie, A., Schmidt, S., & Drusano, G. L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00856-18 · Cited by 30
Hopfner, S. M., Lee, B. S., Kalia, N. P., Miller, M. J., Pethe, K., & Moraski, G. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00398k · Cited by 27
Lawer, A., Tyler, C., Hards, K., Keighley, L. M., Cheung, C., Kierek, F., Su, S., Matikonda, S. S., McInnes, T., Tyndall, J. D. A., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00401 · Cited by 27
Light-Based Anti-Biofilm and Antibacterial Strategies
Kauser, A., Parisini, E., Suarato, G., & Castagna, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082106 · Cited by 28
Therapeutic potential of promiscuous targets in Mycobacterium tuberculosis
Lee, B. S., & Pethe, K. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.06.006 · Cited by 26
Hu, Y., Pertinez, H. E., Liu, Y., Davies, G., & Coates, A. R. M. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz052 · Cited by 26
Soto, R., Pérez‐Herrán, E., Rodríguez, B., Duma, B. M., Cacho, M., Mendoza-Losana, A., Lelièvre, J., Barros-Aguirre, D., Ballell, L., Cox, L. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31157-3 · Cited by 25
Roy, K. K., & Wani, M. A. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696771 · Cited by 25
Boot, M., Jim, K. K., Liu, T., Commandeur, S., Lü, P., Verboom, T., Lill, H., Bitter, W., & Bald, D. (2017) · Scientific Reports · doi:10.1038/s41598-017-10944-4 · Cited by 27
Self-citationAnti-infectives: Can cellular screening deliver?
Keller, T. H., Shi, P., & Wang, Q.-Y. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.06.007 · Cited by 24
Effect of bedaquiline on the functions of rat liver mitochondria
Belosludtsev, K. N., Belosludtseva, N. V., Talanov, E. Y., Tenkov, K. S., Starinets, V. S., Agafonov, A. V., Pavlik, L. L., & Dubinin, M. V. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.06.012 · Cited by 25
Chen, B.-C., Ding, Z., Dai, J.-S., Chen, N.-P., Gong, X., Ma, L., & Qian, C. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.647289 · Cited by 28
Grover, S., Engelhart, C. A., Pérez‐Herrán, E., Li, W., Abrahams, K. A., Papavinasasundaram, K. G., Bean, J. M., Sassetti, C. M., Mendoza-Losana, A., Besra, G. S., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00675 · Cited by 24
Current Molecular Therapeutic Agents and Drug Candidates for Mycobacterium abscessus
Quang, N. T., & Jang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724725 · Cited by 30
Antituberculosis therapy for 2012 and beyond
Lauzardo, M., & Peloquin, C. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.657176 · Cited by 24
Synthetic approaches towards bedaquiline and its derivatives
Calvert, M. B., Furkert, D. P., Cooper, C. B., & Brimble, M. A. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127172 · Cited by 24
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. E., & Berney, M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch20 · Cited by 24
The Medicinal Chemistry of Tuberculosis Chemotherapy
Marriner, G. A., Nayyar, A., Uh, E., Wong, S. Y., Mukherjee, T., Via, L. E., Carroll, M., Edwards, R. L., Gruber, T. D., Choi, I., et al. (2011) · Topics in medicinal chemistry · doi:10.1007/7355_2011_13 · Cited by 29
Krah, A., Zarco‐Zavala, M., & McMillan, D. G. G. (2018) · Open Biology · doi:10.1098/rsob.170275 · Cited by 26
Why Matter Matters: Fast-Tracking Mycobacterium abscessus Drug Discovery
Ganapathy, U. S., & Dick, T. (2022) · Molecules · doi:10.3390/molecules27206948 · Cited by 25
Sabt, A., Abdelraof, M., Hamissa, M. F., & Noamaan, M. A. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300804 · Cited by 22
Lu, R., Schaefer, C. M., Nesbitt, N. M., Kuper, J., Kisker, C., & Sampson, N. S. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00072 · Cited by 22
Development of new drug-regimens against multidrug-resistant tuberculosis
Vasava, M. S., Nair, S., Rathwa, S. K., Patel, D. B., & Patel, H. D. (2018) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2018.07.004 · Cited by 22
Deletion of pknG Abates Reactivation of Latent Mycobacterium tuberculosis in Mice
Khan, M. Z., & Nandicoori, V. K. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02095-20 · Cited by 25
Krah, A. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.06.005 · Cited by 24
Post-translational modifications of the mitochondrial F 1 F O -ATPase
Nesci, S., Trombetti, F., Ventrella, V., & Pagliarani, A. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.08.007 · Cited by 21
Adolph, C., Cheung, C., McNeil, M. B., Jowsey, W. J., Williams, Z. C., Hards, K., Harold, L. K., Aboelela, A., Bujaroski, R. S., Buckley, B. J., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.12.002 · Cited by 21
Benzofuroxan Derivatives as Potent Agents against Multidrug‐Resistant Mycobacterium tuberculosis
Fernandes, G., Campos, D. L., da Silva, I. C., Prates, J. L. B., Pavan, A. R., Pavan, F. R., & dos Santos, J. L. (2021) · ChemMedChem · doi:10.1002/cmdc.202000899 · Cited by 21
The antimicrobial and immunomodulatory effects of Ionophores for the treatment of human infection
Li, G., Oliveira, D. M. P. D., & Walker, M. J. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111661 · Cited by 22
Genetic Approaches to Facilitate Antibacterial Drug Development
Schnappinger, D. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021139 · Cited by 24
Zhou, W., & Faraldo‐Gómez, J. D. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.03.019 · Cited by 21
Yang, L., Guan, D., Valls, M., & Ding, W. (2021) · Pest Management Science · doi:10.1002/ps.6557 · Cited by 20
Panciera, M., Lence, E., Rodríguez, Á., Gracia, B., Aínsa, J. A., Marco‐Marín, C., Rubio, V., Correia, C. R. D., & González‐Bello, C. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114206 · Cited by 21
Targeted Anti-Biofilm Therapy: Dissecting Targets in the Biofilm Life Cycle
Bu, F., Liu, M., Xie, Z., Chen, X., Li, G., & Wang, X. (2022) · Pharmaceuticals · doi:10.3390/ph15101253 · Cited by 23
Patil, S. M., Diorio, A. M., Kommarajula, P., & Kunda, N. K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123920 · Cited by 20
Metadata
- Authors
- Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (United States) (US)
- Vrije Universiteit Amsterdam (NL)
- Johnson & Johnson (France) (FR)
- Corresponding author
- Koul, Anil
- Venue
- Nature Chemical Biology
- Published
- 2007-05-13
- Volume
- 3
- Issue
- 6
- Pages
- 323-324
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2093364655
- Cited by
- 547
- References
- 11
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 27 · 2023: 27 · 2022: 40 · 2021: 50 · 2020: 31 · 2019: 40 · 2018: 36 · 2017: 40 · 2016: 23 · 2015: 33 · 2014: 26 · 2013: 31 · 2012: 22
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, subunit c, atpE, tuberculosis, drug target identification, drug resistance, energy metabolism, antibiotic discovery
- MeSH terms
- Antitubercular Agents, Bacterial Proteins, Binding Sites, Kinetics, Quinolines, Electrophoresis, Gel, Two-Dimensional, Mycobacterium smegmatis, Protein Subunits, ATP Synthetase Complexes, Bacterial Proton-Translocating ATPases, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.